BioPharma APAC - Leading Source of Biopharmaceutical Intelligence in Asia Pacific

LifeScience

Takeda Reports Strong Phase 3 Results For Zasocitinib In Plaque Psoriasis

About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A signifi...

March 30, 2026 | News

Bioptimus Launches STELA Initiative To Build World’s Largest Multimodal Atlas For AI Driven Biology

The global initiative aims to profile up to 100,000 patient specimens to scale M-Optimus, the world model of biology, representing a ~20x increase in scale...

March 27, 2026 | News

Biogen Secures Exclusive Rights To Develop Subcutaneous Biologics Using Alteogen’s ALT B4 Platform

Biogen gains rights to develop and commercialize subcutaneous (SC) formulations for two products utilizing ALT-B4 Alteogen Inc. (KOSDAQ: 196170) ann...

March 27, 2026 | News

Clarity Pharmaceuticals Signs Copper 64 Supply Agreement With Theragenics To Advance Radiopharmaceutical Commercialisation

Clarity Pharmaceuticals (ASX: CU6) ("Clarity" or "Company"), a clinical-stage radiopharmaceutical company with a mission to develop next-generation pr...

March 27, 2026 | News

Hope Medicine Initiates Phase III Trial Of HMI 115 For Endometriosis

Hope Medicine Inc., a science-driven, clinical-stage innovative biopharmaceutical company, announced that the first patient has been dosed in the Phase III...

March 26, 2026 | News

Thermo Fisher Accelerates Clinical Intelligence Leadership With Strategic Clario Acquisition

Further strengthens Thermo Fisher’s position as the trusted partner to pharma and biotech customers, delivering important customer benefits Attracti...

March 25, 2026 | News

Kelun Biotech Reports Strong 2025 Performance With Expanding ADC Pipeline And Commercial Momentum

Revenue amounted to approximately RMB2057.92 million, and gross profit amounted to approximately RMB1478.78 million, representing a year-on-year increase...

March 25, 2026 | News

Innovent Advances Tigulixostat Into Phase 3 To Challenge Standard Gout Therapy

Innovent Biologics, Inc. ("Innovent", HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality med...

March 24, 2026 | News

Belief BioMed And Grand Life Sciences Forge Exclusive Pact To Advance Hemophilia A Gene Therapy

Belief BioMed ("BBM") and Grand Life Sciences Group Co., Ltd. ("Grand Life Sciences") today announced an exclusive collaboration agreement. Under the agree...

March 24, 2026 | News

ImmunityBio Secures Macau Approval For ANKTIVA In BCG Unresponsive Non Muscle Invasive Bladder Cancer

Macau SAR, China regulator grants approval for ANKTIVA® (nogapendekin alfa inbakicept-pmln) in patients with BCG-unresponsive NMIBC with CIS &plusm...

March 23, 2026 | News

GI Innovation Enters Clinical Supply Agreement With Johnson And Johnson To Advance Prostate Cancer Combination Therapy

GI Innovation announced on 19th that it has entered into a clinical supply agreement with Johnson & Johnson to evaluate a combination therapy...

March 23, 2026 | News

Alphamab Oncology Initiates Phase 3 Study Of Bispecific ADC JSKN016 In Triple Negative Breast Cancer

Alphamab Oncology announced that the first patient has been dosed in a phase III clinical study (JSKN016-301) evaluating JSKN016, a novel TROP2/HER3 bispec...

March 23, 2026 | News

MGI Tech Singapore And NUS Partner To Establish Advanced Multi Omics Laboratory For Pharmaceutical Innovation

MGI Tech Singapore Pte. Ltd. ("MGI"), a company dedicated to developing core tools and technologies that drive innovation in life sciences, and the Departm...

March 23, 2026 | News

Dizal Reports ZEGFROVY Achieves Superior Progression Free Survival In Phase 3 WU KONG28 Trial For EGFR Exon20ins NSCLC

Treatment with ZEGFROVY® resulted in statistically significant and clinically meaningful improvement in progression free survival (PFS) over pla...

March 23, 2026 | News

Stay Connected